Notice: Trading of InMed Pharmaceuticals halted at 09:47 AM EST due to "LULD pause". NASDAQ:INM InMed Pharmaceuticals (INM) Stock Price, News & Analysis $5.05 +0.10 (+2.02%) Closing price 04:00 PM EasternExtended Trading$4.18 -0.87 (-17.19%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About InMed Pharmaceuticals Stock (NASDAQ:INM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get InMed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.97▼$8.2750-Day Range$4.05▼$5.5052-Week Range$2.41▼$15.70Volume26.05 million shsAverage Volume2.20 million shsMarket Capitalization$3.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewInMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Read More… InMed Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks24th Percentile Overall ScoreINM MarketRank™: InMed Pharmaceuticals scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for InMed Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of InMed Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InMed Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInMed Pharmaceuticals has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about InMed Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.29% of the outstanding shares of InMed Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverInMed Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InMed Pharmaceuticals has recently decreased by 30.08%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInMed Pharmaceuticals does not currently pay a dividend.Dividend GrowthInMed Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.29% of the outstanding shares of InMed Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverInMed Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InMed Pharmaceuticals has recently decreased by 30.08%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment1.00 News SentimentInMed Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for InMed Pharmaceuticals this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InMed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.85% of the stock of InMed Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 20.12% of the stock of InMed Pharmaceuticals is held by institutions.Read more about InMed Pharmaceuticals' insider trading history. Receive INM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address INM Stock News HeadlinesInMed Shares Rise, Study Indicates Alzheimer's Drug Could Lower NeuroinflammationJanuary 21 at 1:30 PM | marketwatch.comInMed’s Study Highlights Cannabinol’s Potential in SkincareNovember 19, 2024 | markets.businessinsider.com24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.January 21, 2025 | Crypto Swap Profits (Ad)InMed Pharmaceuticals: InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business UpdateNovember 15, 2024 | finanznachrichten.deInMed Pharmaceuticals Makes Progress on Alzheimer’s DrugNovember 15, 2024 | markets.businessinsider.comInMed Pharmaceuticals sets date for annual shareholder meetingSeptember 28, 2024 | investing.comInMed Pharmaceuticals’ (NASDAQ: INM) INM-901: A Promising Candidate for Alzheimer’sAugust 31, 2024 | theglobeandmail.comInMed Pharmaceuticals (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901August 28, 2024 | theglobeandmail.comSee More Headlines INM Stock Analysis - Frequently Asked Questions How have INM shares performed this year? InMed Pharmaceuticals' stock was trading at $4.74 on January 1st, 2025. Since then, INM shares have increased by 7.9% and is now trading at $5.1150. View the best growth stocks for 2025 here. How were InMed Pharmaceuticals' earnings last quarter? InMed Pharmaceuticals Inc. (NASDAQ:INM) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($125.00) EPS for the quarter, topping analysts' consensus estimates of ($175.00) by $50.00. InMed Pharmaceuticals had a negative net margin of 137.41% and a negative trailing twelve-month return on equity of 65.74%. When did InMed Pharmaceuticals' stock split? InMed Pharmaceuticals shares reverse split on Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of InMed Pharmaceuticals? Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InMed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that InMed Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Tesla (TSLA) and PayPal (PYPL). Company Calendar Last Earnings11/10/2021Today1/21/2025Next Earnings (Estimated)2/11/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INM CUSIPN/A CIK1728328 Webwww.inmedpharma.com Phone604-669-7207FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($13.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,680,000.00 Net Margins-137.41% Pretax Margin-137.25% Return on Equity-65.74% Return on Assets-53.57% Debt Debt-to-Equity Ratio0.08 Current Ratio5.07 Quick Ratio4.22 Sales & Book Value Annual Sales$4.60 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value$20.64 per share Price / Book0.25Miscellaneous Outstanding Shares720,000Free Float711,000Market Cap$3.67 million OptionableNot Optionable Beta0.23 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:INM) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.